首页 / 院系成果 / 成果详情页

Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China 期刊论文

编号：

55a03930-1f82-4a3b-afc4-5b29a43594e5
作者：

Xie, Yong(谢勇)#^[1]Zhu, Zhenhua#^[1]Wang, Jiangbin(王江滨)^[2]Zhang, Lingxia^[3];Zhang, Zhenyu^[4];Lu, Hong^[5];Zeng, Zhirong^[6];Chen, Shiyao^[7];Liu, Dongsheng^[1];Lv, Nonghua(吕农华)*^[1]
语种：

英文
期刊：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY ISSN：0066-4804 2018 年 62 卷 9 期 ; SEP
收录：
摘要：

The objective of this study was to investigate the efficacy and safety of 10-day bismuth quadruple therapy with amoxicillin, tetracycline, or clarithromycin and different doses of rabeprazole for first-line treatment of Helicobacter pylori infection. This multicenter, randomized, parallel-controlled clinical trial was conducted between March 2013 and August 2014. A total of 431 H. pylori-infected patients with duodenal ulcers were enrolled and randomized into four treatment groups (1: 1: 1: 1) for 10 days, as follows: (i) a group receiving a low dose of rabeprazole of 10 mg twice a day (b.i.d.) (LR dose) plus bismuth, amoxicillin, and clarithromycin (LR-BAC); (ii) a group receiving LR plus bismuth, amoxicillin, and tetracycline (LR-BAT); (iii) a group receiving a high dose of rabeprazole of 20 mg b.i.d. (HR dose) plus bismuth, amoxicillin, and clarithromycin (HR-BAC); and (iv) a group receiving HR-BAT. Antimicrobial susceptibility was assessed by the Etest method. The primary outcome was H. pylori eradication at 4 weeks after the treatment. The per-protocol (PP) eradication rates in the LR-BAC, LR-BAT, HR-BAC, and HR-BAT groups were 94.1%, 91.9%, 94.8%, and 91.9%, respectively, while the intention-to-treat (ITT) eradication rates in those groups were 87.2%, 87.2%, 87.7%, and 86%, respectively. There was no significant difference between the four groups in PP analysis (P = 0.799) and ITT analysis (P = 0.985). The efficacies of four-treatment therapy were not affected by antibiotic resistance. The adverse events in the four treatment groups were similar; central nervous system (CNS) and gastrointestinal symptoms were the most common reported. Bismuth-containing quadruple therapy with low-dose rabeprazole, amoxicillin, and tetracycline is a good option for first-line treatment of H. pylori infection in a population with high antibiotic resistance.
推荐引用方式
GB/T 7714：

Xie Yong,Zhu Zhenhua,Wang Jiangbin, et al. Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China [J].ANTIMICROBIAL AGENTS AND CHEMOTHERAPY,2018,62(9).
APA：

Xie Yong,Zhu Zhenhua,Wang Jiangbin,Zhang Lingxia,&Lv Nonghua.(2018).Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China .ANTIMICROBIAL AGENTS AND CHEMOTHERAPY,62(9).
MLA：

Xie Yong, et al. "Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China" .ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 62,9(2018).
条目包含文件：

文件类型：PDF,文件大小：

正在加载全文

未找到全文

浏览次数：75  下载次数：0

分享到：

浏览次数：75

下载次数：0

打印次数：0